COSCIENS Biopharma Inc T.CSCI

Avenanthramide pill

[prophetoffactz]

Avenanthramide was the reason Gilles wanted to join CZO originally. More recently, in a December 2022 news release Gilles stated:

"...our avenanthramide program and could be the most significant transformational step we have taken to date in executing on our strategy to expand Ceapro’s business model towards becoming a biopharmaceutical company with the potential to provide an innovative product into very large markets."

In CZO's Feb. 23, 2024 news release it was said: "...the higher the dose without safety concerns, the larger the potential for extending to various inflammation-based diseases."

Subsequently, with single doses administered to the highest 960mg in the avenanthramide pill trial, the May 29, 2024 news release said:

"No significant adverse reactions have been observed during this SAD phase. Based on full report to be completed shortly, members of the Data Safety Monitoring Board will decide on conducting the next step of the Phase 1 study consisting of three additional groups of 8 subjects per group where each subject will receive multiple ascending dose (MAD). The Company expects to initiate the MAD arm during the summer 2024."

The avenanthramide pill clinical trial will test doses 100X that of the exercise inflammation study; including two doses per day. Based on the excercise inflammation study Gilles previously said we may have a very powerful treatment for exercise inflammation. The exercise inflammation study was also said to provide "line of sight" into further developments. Biomarker data was produced. Informing its perspective others have also previously tested avenanthramide in human trials and produced data. A synthetic avenanthramide called Tranilast has also been approved in Japan. A check at PubMed will show that avenanthramide is of interest for many potential large market applications and CSCI has the only capacity to produce natural avenanthramide at commercial scale in the world. CSCI also has a malted technology that can produce the same amount of avenanthramide from a single plant that previously required four plants. In a Feb. 2024 news release samples were said to have been sent to a major potential customer. It was also noted: "The Company is assessing the potential of this product for preventive antimicrobial properties when used to produce oat based nutritional products."

The Angiogenesis Foundation has also produced encouraging results recently with avenanthramide for wound healing.

Gilles has said the non-steroidal anti-inflammatory market is worth ~$50 billion per year. The scientist working on the avenanthramide clinical trial was involved with the recently approved first anti-inflammatory for heart disease and is a noted global authority on inflammation and heart disease. He's also run the largest outpatient clinical trial for COVID and Gilles has noted an interest in COVID heart inflammation. Dr. Li is a student of long-COVID.

 “Given the favorable effects of avenanthramide and the increased knowledge on inflammation-based diseases, especially in the cardiovascular area, we believe this study will offer insights in this first-in-class product for a potential new approach for patients,” commented Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Center and Principal Investigator for this clinical trial." Dec. 2022

Previously CZO noted that it was also  experimenting with avenanthramide with newer PGX carriers with promising results. The following group recently published avenanthramide with yeast beta glucan capsules.

Food Chem

 

•  
•  
•  

. 2024 Aug 1:448:139062.

 doi: 10.1016/j.foodchem.2024.139062. Epub 2024 Mar 20.

Yeast cell wall capsules for delivery of oat biomarker avenanthramide-C

Linyang He 1, Yubo Zhu 1, Xinghui Shen 1, Gang Chen 2, Hang Xiao 3, Jing Wang 4, Chen Tan 5

Affiliations Expand

• PMID: 38531297
•  
• DOI: 10.1016/j.foodchem.2024.139062

Abstract

Avenanthramide-C (AVN-C) is the biomarker for oat with a variety of physiological functions, whereas its application is constrained by low stability and bioavailability. Avenanthramide-C is the biomarker for oat with a variety of physiological functions, whereas its application is constrained by low stability and bioavailability. This study evaluated the potential of yeast cell (YC) and yeast cell wall (YCW) capsules as delivery systems for stabilizing AVN-C. It was observed that these yeast capsules possessed the ellipsoidal morphology and intact structure without visual pores. Additionally, the YCW capsules exhibited higher encapsulation and loading capacity due to the large internal space. The interaction of yeast capsules with AVN-C involved the hydrophobic interactions and hydrogen bonding. Moreover, the loading of AVN-C induced high hydrophobicity inside the yeast capsules, which helped to protect AVN-C against degradation and release AVN-C in a slow and sustained manner in the simulated gastrointestinal tract. The YCW capsules have potential as controlled delivery system for AVN-C, which could be further used as a nutraceutical and added to functional foods.